3.Subjects must have active SLE as demonstrated by a SLEDAI-2K score of ≥6 at the Screening Visit and a clinical SLEDAI (excluding laboratory results) score ≥4 at the Screening and Randomization Visits. Points for arthritis and/or rash must be present at both the Screening and Randomization Visits.